Marty J. Duvall has served as Tocagen’s chief executive officer and as a member of our board of directors since November 2016. He holds over 30 years of oncology drug development and commercialization experience, including building successful oncology teams in both large pharma organizations and biotech companies. Prior to joining Tocagen, Mr. Duvall served as executive vice president, chief commercial officer of ARIAD Pharmaceuticals, Inc., a publicly held biotechnology company, from September 2011 to June 2016, where he led the company’s growth and transformation into a fully integrated, global biotechnology company. From December 2010 to September 2011, he served as senior vice president and general manager for the oncology franchise at Merck & Co., Inc., a publicly held healthcare company. Prior to that, he served in similar capacities at Abraxis Bioscience, Inc., a publicly held biotechnology company now acquired by Celgene; MGI Pharma, Inc., a publicly held biopharmaceutical company now acquired by Eisai Co., Ltd.; and in positions of increasing responsibility at Sanofi US, a publicly held biotechnology company, and its predecessor companies. Mr. Duvall received a bachelor’s degree in chemistry from Muhlenberg College, master’s degree in chemistry from Johns Hopkins University and master’s degree in business administration from the University of Kansas.